Top-Wert für die Zukunft : Genomed - 500 Beiträge pro Seite

[cineman]

Heute Wahnsinnsmeldung herausgebracht !

Swiss-based VC Expects GenoMed Stock To Surpass $1
WEDNESDAY, MARCH 03, 2004 7:01 AM

ST. LOUIS, Mar 3, 2004 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (GMED) , a Next Generation Disease Management(TM) company that uses its expertise in genes to improve patient outcomes, today announced that it has secured potential long-term funding from Pierpoint Investissements SA, a Swiss-based venture capital group registered in the British Virgin Islands.

The agreement calls for a minimum annual investment of $500,000, up to a maximum of $2 million in any one year, for each of the next 10 years in exchange for 12-month restricted shares at a modest discount to the market price. For maintaining this level of annual investment, Pierpoint Investissements SA will keep active warrants for an additional 35 million shares. These can only be converted once the share price of GenoMed reaches at least $1.00. To limit dilution, only 7 million warrants will be convertible each year, so that it will take at least five years to convert this block of 35 million warrants to 12-month restricted shares.

Dr. David Moskowitz, GenoMed`s CEO, said, "We believe that we have achieved equity financing that is minimally dilutive and in the best interests of the company and its existing shareholders. Pierpoint clearly believes that our stock will be worth at least $1, as do I. This financing allows us to move forward aggressively with our scientific program, as well as with our marketing strategy to patients and physicians nationwide."

GenoMed also announced today that the United States Patent and Trademark Office has awarded the company two trademarks that it will use in its marketing efforts: "Next Generation Disease Management" and "Clinical Outcomes Improvement Program."

Dr. Moskowitz is a Harvard and Oxford trained physician, who trained for seven years in Internal Medicine, Biochemistry, and Nephrology at Washington University School of Medicine in St. Louis before spending 11 years on the faculty of St. Louis University School of Medicine. He is a noted pioneer in the field of medical genomics, and has been recognized for his groundbreaking treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic renal failure due to hypertension or type II diabetes.



Es kann nur nach OBEN gehn !!!


cineman

[morchel]

Waahnsinn!



zieht 70% an

morchel

[strategie06]

Hier ging es heute richtig los in Richtung 1$, der von der VC-Gesellschaft (siehe oben) längerfristig angestrebt wird.

GENOMED INC (Other OTC:GMED.PK) Quote data by Reuters

Last Trade: 0.205
Trade Time: 2:05PM ET
Change: 0.082 (66.67%)
Prev Close: 0.123
Open: 0.135

strategie06

[strategie06]

Es geht weiter Richtung 1$.

Last Trade: 0.28
Trade Time: 10:25AM ET
Change: 0.08 (40.00%)
Prev Close: 0.20
Open: 0.215

Strategie06

GenoMed Retains E & E Communications to Assist Investor and Public Relations Programs
Thursday March 4, 6:00 am ET


ST. LOUIS, March 4 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Bulletin Board: GMED - News), a Next Generation Disease Management(TM) company that uses its expertise in genes to improve patient outcomes, today announced that it has retained E & E Communications, Orange County, California, ( http://www.eandecommunications.com ) to assist its public relations and investor relations programs.
ADVERTISEMENT


GenoMed is a leader in the medical revolution which has been made possible by medical genomics. It has proven its ability to improve patient outcomes by identifying the genetic pathways that cause disease.

"Our ability to prevent end-stage kidney disease from diabetes and high blood pressure, and our novel approach to viral diseases, including SARS, avian influenza, and West Nile virus encephalitis, deserve widespread dissemination to the public and to investors. We are pleased to be stepping up our efforts to tell the GenoMed story," said Dr. David Moskowitz, Chairman, CEO and Chief Medical Officer.

"Dr. Moskowitz` extraordinary background, including his education at Harvard and Oxford and his groundbreaking research and clinical efforts in treating kidney disease and West Nile virus, plus his pioneer work in medical genomics, make this an extraordinary company," said Paul Knopick, Principal, E & E Communications. E & E Communications, formed in 1997, serves firms on the NASDAQ National Market and Small Cap, AMEX, Toronto Stock Exchange and OTC BB companies that are fully reporting to the U.S. Securities & Exchange Commission. "We are pleased with the opportunity to introduce GenoMed to the media and investors."

[strategie06]

Genomed nach neuer Finanzierung quasi schuldenfrei.

Strategie06

GenoMed Debt-Free After Forgiveness of $1 Million Loan
Monday March 15, 7:02 am ET


ST. LOUIS, March 15 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Bulletin Board: GMED - News), a Next Generation Disease Management(TM) company that uses its expertise in genomics to improve patient outcomes, today announced that it has secured financing for over $1.5 million to date, triggering the forgiveness of nearly $1.2 million in debt and accrued interest. GenoMed is now essentially debt-free.
ADVERTISEMENT


GenoMed received its final installment of a total of $900,000 in equity financing from Advanced Optics Electronics, Inc. (OTC Bulletin Board: ADOT - News) last week, as well as $380,000 to complete a maximum of $500,000 equity investment by Research Capital. GenoMed has also begun receiving payments from Pierpoint Investissements SA, a venture capital group based in Switzerland. As a result, Research Capital has agreed to forgive nearly $1.2 million in debt and accrued interest because GenoMed was successful in raising at least $1.5 million before December 2004.

Dr. David Moskowitz, GenoMed`s Chairman CEO, said, "We are delighted to have obtained enough financing already this year to be able to retire our debt to Research Capital. The money raised so far has completely turned our financial situation around, and has enabled us to begin our genomics research program in earnest."

Dr. Moskowitz is a Harvard and Oxford trained physician, and is a noted pioneer in the field of medical genomics. He has been recognized for his groundbreaking treatment of diseases associated with the angiotensin I- converting enzyme, such as chronic renal failure due to hypertension or type II diabetes.

About GenoMed

GenoMed is leading the medical revolution which medical genomics has already made possible. GenoMed is a Next Generation Disease Management(TM) company whose mission is to improve patient outcomes by identifying the genetic pathways that cause disease. The Company is currently marketing its treatment for what it believes is the major starting point for most age- related diseases.

[strategie06]

Genomed geht weiter seinen Weg:

Strategie06

First Presumed West Nile Virus Patient in U.S. Responds to GenoMed`s Treatment
Monday April 12, 11:51 am ET


ST. LOUIS, April 12 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Bulletin Board: GMED - News), a Next Generation Disease Management(TM) company that uses its expertise in genes to improve patient outcomes, said today that its protocol has helped the first patient in the U.S. in 2004 who is presumed to have West Nile virus encephalitis. This patient represents the ninth success out of ten consecutive patients to be treated with GenoMed`s protocol.
ADVERTISEMENT


The patient is a 79-year-old male from Scioto County, Ohio who was admitted two weeks ago in a coma due to viral encephalitis. His antibody titers are still pending, but his case so far is consistent with West Nile virus encephalitis. Within 24 hours of starting GenoMed`s treatment, the patient could move his fingers and toes when asked to do so. During the previous ten days he had lain unresponsive and paralyzed. Although it could be argued that he would have gotten better anyway, the speed of his improvement from a disease notorious for the slowness of any recovery, especially in the elderly, argues strongly for the effectiveness of GenoMed`s treatment. Taken with similarly improbable recoveries in eight other patients, the evidence is mounting that GenoMed`s protocol is curative.

West Nile virus is transmitted by mosquitoes and has proven fatal in outbreaks in the U.S., especially to the elderly. Most of the U.S., including California, is bracing for another outbreak of West Nile virus this year following an unseasonably warm spring.

GenoMed`s patent-pending protocol uses blood-pressure drugs that are safe and already familiar to most physicians. They`re carried in every drug store. The protocol, developed by Dr. David Moskowitz, the Company`s Chairman, CEO and Chief Medical Officer, is based on the theory that brain inflammation and death result from an over-response by the patient`s immune system to the West Nile virus. GenoMed`s protocol specifically suppresses the immune system at an early step in its activation. It is the only treatment for West Nile virus encephalitis shown to have a 90 percent cure rate. The results of Dr. Moskowitz`s first eight patients will be published soon in a peer-reviewed medical journal.

The only way to prove that GenoMed`s treatment is effective in West Nile virus encephalitis is to try it in more people. GenoMed is therefore conducting a free, nationwide clinical trial for West Nile virus this summer. The Company would like to eliminate the threat of West Nile virus on the 50th anniversary of the famous 1954 polio field trials which ended the threat of polio in the U.S. For information, click on the "West Nile trial" button at http://www.genomedics.com .

Dr. Moskowitz is a Harvard- and Oxford-educated physician, who trained for seven years in Internal Medicine, Biochemistry, and Nephrology at Washington University School of Medicine in St. Louis before spending 11 years on the faculty of St. Louis University School of Medicine. He is a noted pioneer in the field of medical genomics, and has been recognized for his groundbreaking treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic renal failure due to hypertension or type II diabetes. Dr. Moskowitz`s research on viruses, including West Nile virus, avian influenza ("bird flu"), and SARS, are regarded as innovative approaches for otherwise incurable diseases.

About GenoMed

GenoMed is leading the medical revolution which medical genomics has already made possible. GenoMed is a Next Generation Disease Management(TM) company whose mission is to improve patient outcomes by identifying the genetic pathways that cause disease. After establishing the superiority of a treatment protocol in clinical trials, the Company charges patients a reasonable license fee to use the protocol, which is patented. This summer the Company is conducting a nationwide free clinical trial for West Nile virus encephalitis which will be published before the 2005 West Nile virus season begins. If the Company`s protocol continues to be successful, GenoMed will market it beginning next year. GenoMed is currently marketing its protocol for delaying or even preventing complications of high blood pressure and diabetes, which affect 80 million Americans, as well as emphysema, which affects another 3 million people in the U.S., as well as 60 million smokers.

[strategie06]

News:

Dr. John A. Young Agrees to Educate Physicians and Patients in Amarillo, TX About GenoMed`s Treatments
Tuesday April 20, 8:45 am ET


ST. LOUIS, April 20 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News), a Next Generation Disease Management(TM) company that uses its expertise in genomics to improve patient outcomes, announced today that Dr. John A. Young, a leader in his medical community, has agreed to educate the clinical community of Amarillo for the next four years about GenoMed`s protocols. Amarillo is a metropolitan area with 225,000 residents in the northern Texas Panhandle.
Dr. Young is a partner at Panhandle Pediatrics [tel. [phone]]. He learned of GenoMed`s unique approach to treating disease while doing his own library research on inflammation. He is a Clinical Assistant Professor in the Department of Pediatrics at Texas Tech University Health Sciences Center at Amarillo.

Dr. Young`s influence extends to Texas Tech University Health Science Center at Lubbock. He also is affiliated with the Family Medical Center (FMC), a group of fifteen family practitioners and OB/GYN physicians in Amarillo who see a total of more than 35,000 patients. FMC was just awarded a capitated contract for the Wyatt Clinic, which cares for 6,000 patients, half of whom have type 2 diabetes.

Dr. Young has already begun discussing GenoMed`s protocols to prevent diabetic and hypertensive kidney disease with members of FMC, the Wyatt Clinic, and physicians at both Texas Tech medical school campuses (Amarillo and Lubbock).

About GenoMed

GenoMed is leading the medical revolution which medical genomics has already made possible. The Company`s business model is as novel as its science. GenoMed`s Clinical Outcomes Improvement Program(TM) is available to any patient for the nominal subscription fee of $67 a month ($800 per year). Physicians who participate in GenoMed`s Clinical Outcomes Improvement Network(TM) have the satisfaction of delivering cutting-edge medicine while enhancing their clinical revenue. GenoMed is currently marketing its protocol for delaying complications of high blood pressure and diabetes including kidney failure. Hypertension and diabetes affect 80 million Americans, are responsible for two-thirds of deaths in the U.S., and account for a similar proportion of healthcare costs. GenoMed intends to demonstrate cost-savings by keeping patients healthier.

[strategie06]

Meiner Meinung nach wird GENOMED eine große Zukunft haben, Kursziel auf Jahressicht 1 US$.

Strategie06
News:

GenoMed`s Treatment Showing 100% Response Rate Among Immunocompetent Patients; Nationwide Trial Gaining Momentum
Friday April 23, 8:45 am ET


ST. LOUIS, April 23 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News), a Next Generation Disease Management(TM) company that uses its expertise in genomics to improve patient outcomes, said today that it will be limiting its treatment for West Nile virus encephalitis to immunocompetent patients only, where it has posted a 100% success rate.
ADVERTISEMENT


Ten out of ten patients, including 4 over the age of 70, responded completely to GenoMed`s treatment. The only failure since late August 2003 when the trial began was a young woman with chronic leukemia treated last September.

So far this April, 31 people have downloaded GenoMed`s West Nile virus trial document. These include 4 physicians; 3 public health officers, including one from Manitoba, Canada and one from Arizona; 2 people from blood banks and 2 more from hospitals.

In addition, 6 patients with chronic residual disease after getting West Nile virus encephalitis last summer have signed up for GenoMed`s trial. One patient with right leg paralysis who has been on GenoMed`s treatment during the winter has recovered nearly complete function of his right leg.

GenoMed`s patent-pending protocol uses blood-pressure drugs that are safe and already familiar to most physicians. They`re carried in every drug store. The protocol, developed by Dr. David Moskowitz, the Company`s Chairman, CEO and Chief Medical Officer, is based on the theory that brain inflammation and death result from an over-response by the patient`s immune system to the West Nile virus. GenoMed`s protocol gently suppresses the immune system at an early step in its activation. The results of Dr. Moskowitz`s first eight patients will be published soon in a peer-reviewed medical journal.

If GenoMed`s current 100% cure rate for patients who aren`t immunosuppressed holds up, GenoMed hopes to prevent all deaths and cases of paralysis from West Nile virus encephalitis in the general population this season. Immunosuppressed patients include those with AIDS, those taking chemotherapy for cancer, and organ transplant recipients. GenoMed`s treatment approach is already known not to work for this group, unfortunately. Two other biotechnology companies offer treatments which may benefit immunosuppressed patients.

For the general population, GenoMed recommends beginning its treatment protocol once a person develops fever and flu-like symptoms after a mosquito bite, and not waiting for encephalitis to develop.

GenoMed hopes to eliminate the threat of West Nile virus from the general population on the 50th anniversary of the famous 1954 polio field trials which ended the threat of polio in the U.S. For more information, click on the "West Nile trial" button at http://www.genomedics.com .

Dr. Moskowitz is a Harvard- and Oxford-educated physician, who trained for seven years in Internal Medicine, Biochemistry, and Nephrology at Washington University School of Medicine in St. Louis before spending 11 years on the faculty of St. Louis University School of Medicine. He is a noted pioneer in the field of medical genomics, and has been recognized for his groundbreaking treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic renal failure due to hypertension or type II diabetes. Dr. Moskowitz`s research on viruses, including West Nile virus, avian influenza ("bird flu"), and SARS, are regarded as innovative approaches for otherwise incurable diseases.

About GenoMed

GenoMed is leading the medical revolution which medical genomics has already made possible. GenoMed is a Next Generation Disease Management(TM) company whose mission is to improve patient outcomes by identifying the genetic pathways that cause disease. This summer the Company is conducting a nationwide free clinical trial for West Nile virus encephalitis which will be published before the 2005 West Nile virus season begins. If the Company`s protocol continues to be successful, GenoMed will market it in 2005. GenoMed is currently marketing its protocol for delaying complications, such as kidney failure, of common diseases like high blood pressure and diabetes, which affect 80 million Americans, and emphysema, which affects another 3 million people in the U.S.

[strategie06]

Belarus to Test GenoMed`s Novel Approach to West Nile Virus Encephalitis
Monday April 26, 8:45 am ET


ST. LOUIS, April 26 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News), a Next Generation Disease Management(TM) company that uses its expertise in genomics to improve patient outcomes, said today that the leading experts in West Nile virus encephalitis in Belarus will collaborate with the Company in treating cases of suspected West Nile virus encephalitis this summer. Belarus, formerly a part of the USSR, is now an independent, democratic country of 10.5 million people which lies between Poland and Russia; its capital is Minsk.
ADVERTISEMENT


Researchers from the Research Institute for Epidemiology & Microbiology (RIEM) in Minsk, Belarus, consisting of Dr. Tamara Samoilova, Head of the Lab of Arboviral Infections, Professor of Immunology Leonid Titov, Director of the RIEM, and Professor of Neurology Joseph Protas, Head of the Lab of Viral Neuroinfections will test GenoMed`s protocol for viral encephalitis in Belarus this summer. Normally, there are 50,000 patients with fever every year in Belarus, including 300 cases of viral encephalitis of uncertain cause. Dr. Samoilova has shown that West Nile virus accounts for a significant fraction of the patients with fever and previously undiagnosed viral encephalitis.

The protocol developed by GenoMed uses drugs currently in use by primary care physicians in every country, available in every drug store, and already proven to be safe. The Belarusian experts share GenoMed`s belief that encephalitis and death result from an over-response by a person`s immune system to the West Nile virus. GenoMed`s protocol, which is patent-pending, gently suppresses the immune system, thus potentially saving the patient from paralysis or death.

GenoMed`s treatment has a 100% cure rate so far among immunocompetent patients, including the elderly. No human vaccine yet exists for West Nile virus, nor is any other treatment as inexpensive, safe, or already available like GenoMed`s.

GenoMed is conducting a free clinical trial for West Nile virus this summer in the United States as well as Belarus, and hopes also to recruit patients from Canada, Israel, Europe, and the Middle East. Patients can enroll by clicking on the "West Nile Trial" button at http://www.genomedics.com .

Dr. Moskowitz, GenoMed`s CEO and Chief Medical Officer, is a Harvard- and Oxford-educated physician, who trained for seven years in Internal Medicine, Biochemistry, and Nephrology at Washington University School of Medicine in St. Louis before spending 11 years on the faculty of St. Louis University School of Medicine. He is a noted pioneer in the field of medical genomics, and has been recognized for his groundbreaking treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic renal failure due to hypertension or type II diabetes. Dr. Moskowitz`s novel approach to viral disease, including West Nile virus encephalitis, avian influenza (bird flu), and SARS, are regarded as innovative and potentially useful treatments for currently incurable diseases.

About GenoMed

GenoMed is leading the worldwide medical revolution which medical genomics has already made possible. GenoMed is a Next Generation Disease Management(TM) company whose mission is to improve patient outcomes by identifying the genetic pathways that cause disease. The Company is currently marketing its treatment to prevent kidney failure due to diabetes and high blood pressure, and to delay emphysema.

[strategie06]

GenoMed Retains Well-Known Internet Expert, Joshua Finer, to Assist in Internet Marketing
Tuesday May 4, 9:01 am ET


ST. LOUIS, May 4 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News), a Next Generation Disease Management(TM) company that uses its expertise in genes to improve patient outcomes, said today that it has retained Joshua F. Finer, Founder and President of Software4Parents.com, and a well known Internet marketing expert, to assist the Company in marketing its protocols to patients with diabetes, high blood pressure (hypertension), and emphysema as well as to enroll patients in its free nation-wide clinical trial against West Nile virus.
ADVERTISEMENT


Mr. Finer`s first task has been to implement a Google Internet advertising campaign on a cost-per-click basis.

"The Internet is the first place that Americans go for their health information. For anybody who types `diabetes,` `high blood pressure,` `emphysema,` or `West Nile` into Google, Mr. Finer has already begun directing them towards our Web site, www.genomedics.com," said Dr. David Moskowitz, GenoMed`s Chairman, CEO and Chief Medical Officer.

Joshua F. Finer is an entrepreneur with extensive experience at helping small companies prosper by embracing Internet technologies. He has been seen in national media including The Wall Street Journal, The Chicago Tribune, The Miami Herald, The LA Times, USA Today, The Christian Science Monitor, NBC`s TODAY show, and many other national media venues.

Dr. Moskowitz is a Harvard and Oxford educated physician, who trained for seven years in Internal Medicine, Biochemistry, and Nephrology at Washington University School of Medicine in St. Louis before spending 11 years on the faculty of St. Louis University School of Medicine. He is a noted pioneer in the field of medical genomics, and has been recognized for his groundbreaking treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic renal failure due to hypertension or type II diabetes. Dr. Moskowitz` research on viruses, including West Nile virus, the new avian (bird) flu, and SARS, are also regarded as innovative treatments for diseases that currently have no cure.

About GenoMed

GenoMed is leading the worldwide medical revolution which medical genomics has already made possible. The Company is currently marketing its treatment to prevent kidney failure due to diabetes and high blood pressure, and to delay emphysema.

[strategie06]

Seven Physicians in Amarillo, TX Contract with GenoMed to Distribute the Company`s Treatments to Their 21,000 Patients
Thursday May 6, 12:05 pm ET


ST. LOUIS, May 6 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News), a Next Generation Disease Management(TM) company that uses its expertise in genomics to improve patient outcomes, announced today that Dr. John Young, a leader in his medical community of Amarillo, TX, has convinced seven family physician colleagues to distribute GenoMed`s protocols to their patients. Together, they care for over 21,000 patients.
ADVERTISEMENT


Said Dr. David Moskowitz, GenoMed`s Chief Medical Officer and CEO, "I am delighted by Dr. Young`s effectiveness in educating his medical community about the superior patient outcomes which GenoMed can deliver to patients with hypertension, diabetes, and emphysema. I look forward to working with these outstanding general practitioners, and salute their courage in embracing the latest in medical genomics to help their patients."

About GenoMed

GenoMed is leading the medical revolution which medical genomics has already made possible. The Company`s business model is as novel as its science. GenoMed`s Clinical Outcomes Improvement Program(TM) is available to any patient for the nominal subscription fee of $67 a month ($800 per year). Physicians who participate in GenoMed`s Clinical Outcomes Improvement Network(TM) have the satisfaction of delivering cutting-edge medicine while enhancing their clinical revenue. GenoMed is currently marketing its protocol for delaying complications of high blood pressure and diabetes including kidney failure. Hypertension and diabetes affect 80 million Americans, are responsible for two-thirds of deaths in the U.S., and account for a similar proportion of healthcare costs. GenoMed intends to demonstrate cost-savings by keeping patients healthier.


Das ist ein sehr interessantes Business-Modell, da kann jeder Patient selbst entscheiden, ob er daran teil nimmt. Das kostet natürlich schon etwas und verspricht dadurch riesige Einnahme-Möglichkeiten, aber das Wichtigste ist immer, das die Heilung funktioniert oder?

GenoMed`s Clinical Outcomes Improvement Program(TM) is available to any patient for the nominal subscription fee of $67 a month ($800 per year).

Kursziel auf Jahressicht 1 US$.

CU
Strategie06

[strategie06]

Jetzt hat Genomed erst einmal ein schlagkräftiges Management-Team aufgebaut, um weiter zu expandieren.

Bin ich hier eigentlich Allein-Unterhalter? Wäre schade für euch bei diesem Potential für die Zukunft (Kursziel 1 US$).

CU
Strategie06


GenoMed Adds to Management Team
Tuesday May 11, 9:35 am ET


ST. LOUIS, May 11 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News), a Next Generation Disease Management(TM) company that uses its expertise in genes to improve patient outcomes, said today that it has hired three additional full-time employees: a Chief Financial Officer, a Vice President for Marketing, and a Chief Technical Officer.
Ms. Robyn L. Owens was hired as Chief Financial Officer. She has twenty-two years` experience in the health care industry, half on the payor`s side and half on the providers` side. Her experience includes contracts, claims, customer service, and bringing private physicians into managed care. Her expertise is in finance, in particular hospital and physician contracting. She is a member of Medical Group Managers Association, Group Health Association of America, and National Association of Female Executives.

Ms. Ellen Jones was hired as Vice President for Marketing. She has experience marketing Internet solutions to banks, tax and regulatory information to accountants and tax lawyers, as well as temporary staffing solutions. She has extensive experience translating complex technical information into everyday language.

Mr. Andy O`Guin was hired as Chief Technical Officer. He comes from a private St. Louis biotechnology company engaged in anti-viral drug discovery. He has experience in genotyping, assay development, and drug discovery. He will oversee research outsourced to GenoMed`s partners.

Said Dr. David Moskowitz, GenoMed`s CEO and Chairman, "After a careful search, GenoMed now has a wonderful management team, one that is nimble, experienced, and personable. We are poised for growth."

About GenoMed

GenoMed is leading the worldwide medical revolution which medical genomics has already made possible. In addition to looking for new disease-predisposition genes, the Company is currently marketing its treatment to prevent kidney failure due to diabetes and high blood pressure, and to delay emphysema.

[strategie06]

GenoMed Signs Genotyping Contract with Genome Quebec
Wednesday May 19, 9:35 am ET


MONTREAL and ST. LOUIS, May 19 /PRNewswire-FirstCall/ -- The McGill University and Genome Quebec Innovation Centre has announced the signing of a service agreement with GenoMed (Pink Sheets: GMED - News), a U.S. company located in St. Louis, Missouri that specializes in using genomics to practice better medicine.
The Illumina genotyping solution drove this contract win for Quebec. The McGill University and Genome Quebec Innovation Centre is one of the rare centres in the world to have integrated this exclusive technology.

Said David Moskowitz, Chairman and CEO of GenoMed, "Our genotyping consists of two stages: screening a very large number of SNPs, and validating a smaller number of them. Only Illumina`s genotyping technology lets us screen tens of thousands of SNPs simultaneously. We think we`ve gotten literally the best deal in the world by having the Montreal Genome Centre perform this large-scale screening project."

In the words of Paul L`Archeveque, President and CEO of Genome Quebec, "This service agreement clearly illustrates the organization`s desire to make scientific research more credible by creating a favorable, attractive environment that will make Quebec a centre of research excellence." Its reputation, expertise and high-quality services mean that the McGill University and Genome Quebec Innovation Centre can attract clients from Quebec, the rest of Canada, New England and elsewhere across the U.S.

About Genome Quebec

Genome Quebec was created to make Quebec a member of the privileged ranks of international leaders in genomics and proteomics research. In combining considerable financial resources with a system for managing major research projects, Genome Quebec represents a new development model that makes it especially possible to support the best teams of researchers from academic, industrial and government settings. Its mission is to mobilize the research and business sectors to continue growing Quebec`s presence and role in the life sciences sector. Genome Quebec manages a portfolio worth some $220 million.

About GenoMed

GenoMed is leading the clinical revolution which medical genomics already makes possible. GenoMed is a Next Generation Disease Management(TM) company whose mission is to improve patient outcomes by identifying the genetic pathways that cause disease. GenoMed has published the only paper in the medical literature showing that regression (prevention) of kidney failure due to high blood pressure and diabetes can be achieved. High blood pressure and diabetes affect 80 million Americans.

[Tschonko]

Hallo,
Freitag und heute die reinste Achterbahnfahrt.
Weiß jemand mehr? SEC Bericht vom Freitag? Aber warum?

http://biz.yahoo.com/e/040604/gmed.pk10qsb.html

Der Bericht ist so lang, will ihn hier nicht reinstellen.

Grüße

[strategie06]

GenoMed`s Novel Treatment Working for Post-West Nile Virus Encephalitis Syndrome
Friday June 18, 9:35 am ET


ST. LOUIS, June 18 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News), a Next Generation DM(TM) (Disease Management) company that uses its expertise in genomics to improve clinical outcomes, announced today that its unique, patent-pending approach to West Nile virus encephalitis appears to work even months after the acute episode.
ADVERTISEMENT


Some people with West Nile virus encephalitis fail to recover completely even long after the acute episode. They may have headache, continued paralysis, weakness, fatigue, or tremors. Such residual symptoms are called post-West Nile virus encephalitis syndrome. West Nile virus is not the only virus which can cause them. Polio can do the same thing.

GenoMed has now seen gratifying responses in two patients with post-WNV encephalitis syndrome. One patient had constant headaches for seven months after her episode of WNV encephalitis last summer. Her headaches disappeared within a week of starting GenoMed`s experimental approach. A second patient, Mr. Thomas Cook, began GenoMed`s treatment two months after West Nile virus encephalitis, when he was still paralyzed in his right leg. His story appeared yesterday on WCVB Channel 5, Boston at:

http://www.thebostonchannel.com/health/3430371/detail.html

GenoMed`s goal is to eliminate the threat of West Nile virus from the general population on the 50th anniversary of the famous 1954 polio field trials which ended the threat of polio in the U.S.

For more information, click on the "West Nile trial" link at http://www.genomedics.com .

[strategie06]

GenoMed`s Dr. David Moskowitz Featured on Wall Street Reporter; Says Genomics-Based Preventive Medicine Best Cure for Healthcare Crisis
Wednesday June 23, 4:15 pm ET


ST. LOUIS, June 23 /PRNewswire-FirstCall/ -- GenoMed, Inc. ("the Company" or "GenoMed") (Pink Sheets: GMED - News), a St. Louis, Missouri-based Next Generation Disease Management company, announced today that its Chairman and CEO, Dr. David Moskowitz, is featured in Wall Street Reporter Magazine ( http://www.wallstreetreporter.com/linked/GenoMed.html ) discussing how preventive molecular medicine as GenoMed practices it can significantly lower healthcare costs.
ADVERTISEMENT




GenoMed has aligned its business model with optimizing public health. The Company`s goal is to find the least expensive, fastest, and safest way to improve patient outcomes. The Company has already accomplished this for diabetes, hypertension, and emphysema, which affect over 83 million Americans. This summer GenoMed will conduct a free national trial for West Nile virus using already existing, FDA-approved drugs.

GenoMed`s business model is ideal for today`s political climate. It is tailor-made for Health Savings Accounts (HSAs). Rather than waiting for bureaucratic health plans to embrace its Next Generation Disease Management(tm), GenoMed is now encouraging patients who control their own Health Savings Account to sign up themselves for GenoMed`s modestly priced services.

About GenoMed

GenoMed`s goal is to eliminate the threat of West Nile virus from the general population on the 50th anniversary of the famous 1954 polio field trials which ended the threat of polio in the U.S. For more information, click on the "West Nile trial" link at http://www.genomedics.com .